Mexiletine
Antiarrhythmics, Class Ib
- Drug class
- Antiarrhythmics, Class Ib
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 18
Overview
Plain-language summary, compiled from the cited regulatory records
Mexiletine hydrochloride capsules, USP are a medication approved for treating specific types of ventricular arrhythmias, such as sustained ventricular tachycardia, that pose a life-threatening risk [1]. It belongs to the drug class of antiarrhythmics, specifically Class Ib [1]. Due to potential proarrhythmic effects, mexiletine is generally not recommended for less severe arrhythmias, and treatment of patients with asymptomatic ventricular premature contractions should be avoided [1].
Mexiletine hydrochloride capsules are available under various brand names [1]. The decision to initiate treatment with mexiletine should be made carefully by a physician, considering the drug's potential risks and benefits [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 16 | May 22, 2026 |
| US United States | FDA | 2 | February 5, 2025 |
GBUnited Kingdom· MHRA
16 products
Uses
Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.
How to take
USUnited States· FDA
2 products
Uses
INDICATIONS AND USAGE
Mexiletine hydrochloride capsules, USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended.
Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital.
Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias.
Drug interactions
Known interactions involving Mexiletine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB542890003 · revised January 30, 2026
- [2]FDA DailyMed · 0ff45dbf-b555-4f… · revised October 18, 2024 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.